lmat20220224_8k.htm
false 0001158895 0001158895 2022-02-24 2022-02-24
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  February 24, 2022
 
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-33092
 
Delaware
04-2825458
(State or other jurisdiction of
(IRS Employer
incorporation)
Identification No.)
 
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
 
781-221-2266
(Registrants telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT 
The Nasdaq Global Market
 
 

 
Item 2.02. Results of Operations and Financial Condition.
 
On February 24, 2022, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Report.
 
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
 
Item 9.01. Financial Statements and Exhibits.
 
The following exhibits are furnished or filed as part of this Report, as applicable:
 
 
(d)
Exhibits.
 
 
Exhibit No.
 
Description
     
99.1
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
Exhibit Index
 
Exhibit No.
 
Description
     
99.1
 
Press release issued by LeMaitre Vascular, Inc. on February 24, 2022.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
 
Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
   
LeMaitre Vascular, Inc.
                 
                 
Date: February 24, 2022
 
 
 
By:
 
Joseph P. Pellegrino, Jr.
/s/ JOSEPH P. PELLEGRINO, JR.
               
Joseph P. Pellegrino, Jr.
Chief Financial Officer
 
 
ex_339775.htm

Exhibit 99.1

 

LeMaitre Q4 2021 Financial Results

 

BURLINGTON, MA, February 24, 2022 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2021 results, announced a $0.125/share quarterly dividend (+14%) and provided guidance.

 

Q4 2021 Financial Results

 

 

Sales of $39.5mm, +5% (+6% organic) vs. Q4 2020

 

Op. income of $8.3mm, -13%

 

Op. margin of 21%

 

Net income of $6.2mm, -12%

 

Earnings of $0.28 per diluted share, -18%

 

Cash and investments +$2.9mm to $70.0mm

 

Q4 2021 sales were driven by bovine grafts (Artegraft) and bovine patches (XenoSure). The Americas was up 8%, EMEA was up 1%, and Asia/Pac was down 3%.

 

The gross margin increase to 65.7% (vs. 65.0% in Q4 2020) was driven by higher average selling prices and an improved sales mix.

 

Op. income decreased 13% to $8.3mm in Q4 2021, driven by a 17% headcount increase as well as higher clinical and regulatory expenses.

 

George LeMaitre, Chairman and CEO, said, “Despite considerable hiring we produced a Q4 op. margin of 21% and the dividend is now increasing for the 11th straight year.”

 

2021 Financial Results

 

Sales growth of 19% for full-year 2021 was driven by bovine grafts, valvulotomes, bovine patches and carotid shunts. Op. income and net income both grew 27% in 2021 as sales growth outpaced op. expense growth. 2021 EBITDA of $45.8mm coupled with the follow-on stock offering enabled the final Artegraft acquisition loan pay-down during the year and a record cash balance of $70.0mm at year-end.

 

Business Outlook

 

  Q1 2022 Guidance
Sales

$37.7mm - $39.7mm

(Mid: $38.7mm, +8%, +10% Org.)

Gross Margin 66.2%
Op. Income

$7.1mm - $8.4mm

(Mid: $7.7mm, -3%)

EPS

$0.26 - $0.30

(Mid: $0.28, -1%)

   
  2022 Full Year Guidance
Sales

$162mm - $166mm

(Mid: $164mm, +6%, +8% Org.)

Gross Margin 67.2%
Op. Income

$38.5mm - $41.1mm

(Mid: $39.8mm, +9%)

EPS

$1.35 - $1.45

(Mid: $1.40, +12%)

 

 

Quarterly Dividend

 

On February 22, 2022, the Company's Board of Directors approved a quarterly dividend of $0.125/share of common stock. The dividend will be paid on March 24, 2022 to shareholders of record on March 8, 2022.

 

 

Share Repurchase Program

 

On February 22, 2022, the Company's Board of Directors authorized the repurchase of up to $20.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 22, 2023, unless extended by the Board.

 

 

 

Conference Call Reminder

 

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 800-773-2954 (+1 847-413-3731 for international callers), using passcode 50283055. For individuals unable to join the live conference call, a replay will be available on the Company's website.

 

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

 

 

About LeMaitre

 

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

 

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

 

For more information about the Company, please visit http://www.lemaitre.com.

 

 

Use of Non-GAAP Financial Measures

 

LeMaitre management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

 

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.

 

 

Forward-Looking Statements

 

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with foreign regulatory requirements to market and sell our products outside the United States; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

 

 

CONTACT: 

J.J. Pellegrino, CFO, LeMaitre
781-425-1691
jjpellegrino@lemaitre.com

 

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands)

 

   

December 31, 2021

   

December 31, 2020

 
   

(unaudited)

         

Assets

               
                 

Current assets:

               

Cash and cash equivalents

  $ 13,855     $ 26,764  

Short-term marketable securities

    56,104       214  

Accounts receivable, net

    19,631       19,552  

Inventory and other deferred costs

    46,104       45,115  

Prepaid expenses and other current assets

    4,189       2,618  

Total current assets

    139,883       94,263  
                 

Property and equipment, net

    17,059       15,036  

Right-of-use leased assets

    15,071       16,066  

Goodwill

    65,945       65,945  

Other intangibles, net

    52,710       58,905  

Deferred tax assets

    1,566       1,686  

Other assets

    568       909  
                 

Total assets

  $ 292,802     $ 252,810  
                 
                 

Liabilities and stockholders' equity

               
                 

Current liabilities:

               

Current portion of long-term debt

  $ -     $ 2,500  

Accounts payable

    2,340       2,394  

Accrued expenses

    16,332       17,525  

Acquisition-related obligations

    1,271       772  

Lease liabilities - short-term

    1,870       1,954  

Total current liabilities

    21,813       25,145  
                 

Long-term debt, net

    -       35,532  

Lease liabilities - long-term

    14,067       14,791  

Deferred tax liabilities

    70       127  

Other long-term liabilities

    2,701       4,643  

Total liabilities

    38,651       80,238  
                 

Stockholders' equity

               

Common stock

    235       221  

Additional paid-in capital

    181,630       114,924  

Retained earnings

    88,125       70,554  

Accumulated other comprehensive loss

    (3,435 )     (1,525 )

Treasury stock

    (12,404 )     (11,602 )

Total stockholders' equity

    254,151       172,572  
                 

Total liabilities and stockholders' equity

  $ 292,802     $ 252,810  

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

 

   

For the three months ended

   

For the year ended

 
   

December 31, 2021

   

December 31, 2020

   

December 31, 2021

   

December 31, 2020

 
                                 

Net sales

  $ 39,503     $ 37,548     $ 154,424     $ 129,366  

Cost of sales

    13,547       13,146       53,042       44,748  
                                 

Gross profit

    25,956       24,402       101,382       84,618  
                                 

Operating expenses:

                               

Sales and marketing

    7,445       5,912       27,655       23,700  

General and administrative

    6,753       6,076       25,501       22,501  

Research and development

    3,457       2,869       11,801       10,099  

Gain on sale of building

    -       -       -       (470 )

Total operating expenses

    17,655       14,857       64,957       55,830  
                                 

Income from operations

    8,301       9,545       36,425       28,788  
                                 

Other income (expense), net

                               

Interest income

    141       13       197       207  

Interest expense

    (526 )     (579 )     (2,219 )     (1,310 )

Foreign currency gain (loss)

    (11 )     (48 )     (116 )     (329 )
                                 

Income before income taxes

    7,905       8,931       34,287       27,356  
                                 

Provision for income taxes

    1,730       1,898       7,380       6,136  
                                 

Net income

  $ 6,175     $ 7,033     $ 26,907     $ 21,220  
                                 

Earnings per share of common stock

                               

Basic

  $ 0.28     $ 0.35     $ 1.27     $ 1.05  

Diluted

  $ 0.28     $ 0.34     $ 1.25     $ 1.04  
                                 

Weighted - average shares outstanding:

                               

Basic

    21,860       20,380       21,157       20,246  

Diluted

    22,138       20,621       21,475       20,479  
                                 
                                 

Cash dividends declared per common share

  $ 0.110     $ 0.095     $ 0.440     $ 0.380  

 

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

 

   

For the three months ended

   

For the year ended

 
   

December 31, 2021

   

December 31, 2020

   

December 31, 2021

   

December 31, 2020

 
       $    

%

      $    

%

      $    

%

       $    

%

 

Net Sales by Geography

                                                               

Americas

  $ 25,948       65 %   $ 24,002       64 %   $ 102,265       66 %   $ 81,470       63 %

Europe, Middle East and Africa

    10,932       28 %     10,854       29 %     42,132       27 %     39,193       30 %

Asia Pacific

    2,623       7 %     2,692       7 %     10,027       7 %     8,703       7 %

Total Net Sales

  $ 39,503       100 %   $ 37,548       100 %   $ 154,424       100 %   $ 129,366       100 %

 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

 

Reconciliation between GAAP and Non-GAAP sales growth:

                       

For the three months ended December 31, 2021

                       

Net sales as reported

  $ 39,503                  

Impact of currency exchange rate fluctuations

    372                  

Adjusted net sales

          $ 39,875          
                         

For the three months ended December 31, 2020

                       

Net sales as reported

  $ 37,548                  

Adjusted net sales

          $ 37,548          
                         

Adjusted net sales increase for the three months ended December 31, 2021

    $ 2,327       6 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected sales growth:

                       

For the three months ending March 31, 2022

                       

Net sales per guidance (midpoint)

  $ 38,740                  

Impact of currency exchange rate fluctuations

    722                  

Adjusted projected net sales

          $ 39,462          
                         

For the three months ended March 31, 2021

                       

Net sales as reported

  $ 35,883                  

Adjusted net sales

          $ 35,883          
                         

Adjusted projected net sales increase for the three months ending March 31, 2022

    $ 3,579       10 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected sales growth:

                       

For the year ending December 31, 2022

                       

Net sales per guidance (midpoint)

  $ 163,990                  

Impact of currency exchange rate fluctuations

    2,018                  

Adjusted projected net sales

          $ 166,008          
                         

For the year ended December 31, 2021

                       

Net sales as reported

  $ 154,424                  

Adjusted net sales

          $ 154,424          
                         

Adjusted projected net sales increase for the year ending December 31, 2022

    $ 11,584       8 %

 

 

   

For the year ended

 
   

December 31, 2021

   

December 31, 2020

 

Reconciliation between GAAP and Non-GAAP EBITDA

               

Net income as reported

  $ 26,907     $ 21,220  

Interest (income) expense, net

    2,022       1,103  

Amortization and depreciation expense

    9,475       8,224  

Provision for income taxes

    7,380       6,136  
                 

EBITDA

  $ 45,784     $ 36,683  
                 

EBITDA percentage increase (decrease)

            25 %